Join us online at COVERGENCE OCT 22-23
The University Tech/Startup Gap Fund and Accelerator Summit
- 20 in-depth gap fund/accelerator program reviews
- Breakout and group discussions on common challenges
- Corporate and Investor partnering panels
- Networking web-site and associated materials
A new licensing agreement will help farmers and veterinarians fight early-life diarrhea in dairy and beef cattle.
Bayer Animal Health and ParaTheraTech (PTT) have signed a global agreement to advance new Cryptosporidiosis treatment options for these farm animals.
Bayer will develop and commercialize novel compounds based on knowledge and intellectual property licensed by PTT from the University of Washington (UW).
According to the company, Cryptosporidium is a highly infectious diarrhea pathogen and is one of the main causes of death in young calves. The problem can be observed at 30 to 70 percent of the world’s farms.
“Cryptosporidiosis is considered one of the biggest unsolved parasite problems in dairy cattle,” said Douglas Hutchens, DVM, Bayer Animal Health’s chief veterinary officer and head of drug discovery and external innovation.
“The license agreement will enable us to support farmers and veterinarians in tackling this health and well-being concern: early-life diarrhea caused by Cryptosporidium.”
UW assisted PTT with patent filing and strategy, provided an Innovation Gap Fund grant, helped with other funding, and supported the company in licensing exclusive rights to the compound.